Shantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable medicines at its Hyderabad facility. This partnership highlights India's growing role in advanced pharmaceutical manufacturing, particularly for high-demand diabetes and obesity therapies. Shantha's FDA-approved, automated fill-finish lines will produce these critical components, underscoring the company's expanding capabilities in contract manufacturing for biologics.

HYDERABAD, India, June 30, 2026 /PRNewswire/ -- Shantha Biologics today announced that it has entered into an outsourcing agreement with Novo Nordisk to provide cartridge…

Shantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable medicines at its Hyderabad facility.…

Shantha Biologics partners with Novo Nordisk to provide cartridge fill-finish services for injectable medicines at its Hyderabad facility.